Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SVN53-67/M57-KLH in Multiple Myeloma Receiving Lenalidomide Maintenance
NCT02334865Phase 1Active, not recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Apr 2017
- Primary completion
- Sep 2022
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of SurVaxM in multiple myeloma (MM) (2 arms), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Toxicity profile of the SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant plus sargramostim up to 24 weeks. Started Apr 2017; status: active, not recruiting.
02
Drugs
SurVaxM
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02334865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02334865.